Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01907360 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of HLD200 in Children and Adolescents With ADHD
A Phase 1 study, sponsored by Ironshore Pharmaceuticals and Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT01907360 is a Phase 1 study that has completed, run by Ironshore Pharmaceuticals and Development. The registered enrollment target is 29 participants.
The verdict
NCT01907360, a Phase 1 study, has completed, sponsored by Ironshore Pharmaceuticals and Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This study was designed to assess the pharmacokinetic effects of a single dose of HLD200 (methylphenidate hydrochloride) in children and adolescents with ADHD.
Interventions
- DRUG HLD200 (methylphenidate hydrochloride)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2013-08 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01907360
The ClinicalTrials.gov registry entry for NCT01907360 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ironshore Pharmaceuticals and Development, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HLD200 (methylphenidate hydrochloride) is the first listed.
NCT01907360 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01907360 about?
NCT01907360 is a clinical study titled "Pharmacokinetics of HLD200 in Children and Adolescents With ADHD". This study was designed to assess the pharmacokinetic effects of a single dose of HLD200 (methylphenidate hydrochloride) in children and adolescents with ADHD.
What is the current status of trial NCT01907360?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2013-08. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01907360?
The interventions under investigation include: HLD200 (methylphenidate hydrochloride) (DRUG).
Who is sponsoring clinical trial NCT01907360?
This trial is sponsored by Ironshore Pharmaceuticals and Development, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.